THE ROLE OF GLIMEPIRIDE IN THE MODERN COMBINED HYPOGLYCEMIC THERAPY OF DIABETES MELLITUS TYPE 2


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The review deals with the analysis of randomized controlled clinical trials of the efficiency and safety of gLimepiride, both as part of monotherapy and in combination with other antidiabetic agents. For the analysis were selected only those studies which aim was to evaluate the effectiveness of the correction of carbohydrate metabolism and decrease of glycemia. It is concluded that the addition of glimepiride to hypoglycemic therapy is accompanied by marked clinical effect and good safety profile, which shows lower incidence of hypoglycemia and no or negligible increase of body weight.

Full Text

Restricted Access

About the authors

Tatiana Yulievna Demidova

Russian Medical Academy of Postgraduate Education

Email: t.y.demidova@gmail.com
MD, Professor; Professor of the Department of endocrinology and diabetology 125315, Moscow, 20 Chasovaya St

References

  1. International diabetes federation. IDF Diabetes Atlas, 2015. 7th edition.
  2. Дедов И.И., Шестакова М.В., Викулова О.К. Государственный регистр сахарного диабета в Российской Федерации: статус 2014 г. и перспективы развития. Сахарный диабет. 2015;18(3):5-22.
  3. Dedov I., Shestakova M., Benedetti M.M., Simon D., Pakhomov I., Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult Russian population (NATION study). Diabetes Res. Clin. Pract. 2016;115:90-5.
  4. Fowler M.J. Microvascular and macrovascular complications of diabetes. Clin. diabetes. 2008;26(2):77-82.
  5. Dedov I.I. Standards of specialized diabetes care. Edited by I.I. Dedov, M.V. Shestakova. Diabetes Mellit. 2015;18(1S):1.
  6. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., Peters A.L., Tsapas A., Wender R., Matthews D.R. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2012;35(6):1364-79.
  7. Дедов И.И., Шестакова М.В., Галстян Г.Р., Григорян О.Р., Есаян Р.М., Калашников В.Ю., Кураева Т.Л., Липатов Д.В., Майоров А.Ю., Петеркова В.А., Смирнова О.М., Старостина Е.Г., Суркова Е.В., Сухарева О.Ю., Токмакова А.Ю., Шамхалова М.Ш., Ярек-Мартынова И.Р. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). Сахарный диабет. 2015;18(1S).
  8. Государственный реестр лекарственных средств, Амарил, инструкция по применению. March 2009. http://grls.rosminzdrav.ru/
  9. Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., Kiowski W., Amann F.W., Gruber D., Harris S., Burger W. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur. Heart J. 1999;20(6):439-46.
  10. Loubani M., Fowler A., Standen N.B., Galinanes M. The effect of gliclazide and glibenclamide on preconditioning of the human myocardium. Eur. J. Pharmacol. 2005;515(1-3):142-9.
  11. Kiowski W., Amann F.W., Gruber D., Harris S., Burger W. Sulfonylureas and ischaemic preconditioning. 1999:439-46.
  12. Nagashima K., Takahashi A., Ikeda H., Hamasaki A., Kuwamura N., Yamada Y., Seino Y. Sulfonylurea and non-sulfonylurea hypoglycemic agents: pharmachological properties and tissue selectivity. Diabetes Res. Clin. Pract. 2004;66:S75-8.
  13. Ovünç K. Effects of glibenclamide, a K(ATP) channel blocker, on warm-up phenomenon in type II diabetic patients with chronic stable angina pectoris. Clin. Cardiol. 2000;23(7):535-9.
  14. Monami M., Luzzi C., Lamanna C., Lamanna C., Chiasserini V., Addante F., Desideri C.M., Masotti G., Marchionni N., Mannucci E. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes Metab. Res. Rev. 2006;22(6):477-82.
  15. Martin S., Kolb H., Beuth J., Van Leendert R., Schneider B., Scherbaum W.A. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrolective cohort study. Diabetologia. 2003;46(12):1611-7.
  16. Scholz G.H., Schneider K., Knirsch W., Becker G. Efficacy and tolerability of glimepiride in daily practice. Clin. Drug Investig. 2001;21(9):597-604.
  17. Weitgasser R., Lechleitner M., Luger A., Klingler A. Effects of glimepiride on HbA1c and body weight in Type 2 diabetes: Results of a 1,5-year follow-up study. Diabetes Res. Clin. Pract. 2003;61(1):13-9.
  18. Khabsa M., Giles C.L. The number of scholarly documents on the public web. PLoS One. 2014;9(5):e93949.
  19. Lewin A.J., Arvay L., Liu D., Patel S., von Eynatten M., Woerle H.-J. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther. 2012;34(9):1909-19.e15.
  20. Seino Y., Miyata Y., Hiroi S., Hirayama M., Kaku K. Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study. Diabetes, Obes. Metab. 2012;14(10):927-36.
  21. Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H., Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes. Metab. 2007;9(5):733-45.
  22. Tajima N., Kadowaki T., Odawara M., Nishii M., Taniguchi T., Arjona Ferreira J.C. Addition of sitagliptin to ongoing glimepiride therapy in Japanese patients with type 2 diabetes over 52 weeks leads to improved glycemic control. Diabetol Int. 2011;2(1):32-44.
  23. Kikuchi M., Haneda M., Koya D., Tobe K., Onishi Y., Couturier A., Mimori N., Inaba Y., Goodman M. Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2010;89(3):216-23.
  24. Garber A.J., Foley J.E., Banerji M.A., Ebeling P., Gudbjörnsdottir S., Camisasca R.P., Couturier A., Baron M.A. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes. Metab. 2008;10(1 1):1047-56.
  25. Giorgino F., Benroubi M., Sun J.-H., Zimmermann A.G., Pechtner V. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015;38(12):2241-9.
  26. Buse J.B., Henry R.R., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27(11):2628-35.
  27. Marre M., Shaw J., Brändle M., Bebakar W.M., Kamaruddin N.A., Strand J., Zdravkovic M., Le Thi T.D., Colagiuri S. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med. 2009;26(3):268-78.
  28. Strojek K., Yoon K.-H., Hruba V., Sugg J., Langkilde A.M., Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther. 2014;5(1):267-83.
  29. Dungan K.M., Weitgasser R., Perez Manghi F., Pintilei E., Fahrbach J.L., Jiang H.H., Shell J., Robertson K.E. A 24-week study to evaluate the efficacy and safety of once weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8). Diabetes Obes. Metab. 2016;18(5):475-82.
  30. Stratton I.M., Adler A.I., Neil H.A., Matthews D.R., Manley S.E., Cull C.A., Hadden D., Turner R.C., Holman R.R. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12.
  31. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., Marre M., Cooper M., Glasziou P., Grobbee D., Hamet P., Harrap S., Heller S., Liu L., Mancia G., Mogensen C.E., Pan C., Poulter N., Rodgers A., Williams B., Bompoint S., de Galan B.E., Joshi R., Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 2008;358:2560-72.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies